In the PERSEO registry, 75% of elderly patients (≥80 years) post-PCI received prolonged triple antithrombotic therapy, experiencing a 21% incidence of bleeding and 21% all-cause mortality.
This critical analysis highlights a concerning disconnect between contemporary clinical practice and evidence-based guidelines, as frail elderly patients frequently receive inappropriately prolonged triple antithrombotic therapy post-PCI, leading to high rates of bleeding and mortality.
Dziewierz et al. (Sun,) conducted a letter in Atrial fibrillation and coronary disease post-percutaneous coronary intervention. Triple antithrombotic therapy vs. Dual antithrombotic therapy was evaluated. In the PERSEO registry, 75% of elderly patients (≥80 years) post-PCI received prolonged triple antithrombotic therapy, experiencing a 21% incidence of bleeding and 21% all-cause mortality.